What is the key role of CD140a antibody in cell biology research?

I. What is CD140a Antibody and Its Molecular Basis?

CD140a antibody is a highly specific immunoglobulin that recognizes and binds to the CD140a molecule, also known as platelet-derived growth factor receptor alpha (PDGFRα). The CD140a molecule belongs to the type III tyrosine kinase receptor superfamily, with a structure comprising an extracellular domain, transmembrane domain, and intracellular domain. The extracellular domain consists of five immunoglobulin-like domains responsible for binding PDGF ligands, while the intracellular domain possesses tyrosine kinase activity that plays a central role in signal transduction. CD140a antibodies are typically produced through hybridoma technology or recombinant DNA technology, with their antigen-binding sites specifically recognizing particular epitopes on the CD140a molecule. This specific binding forms the foundation of their applications in scientific research.

From an immunological perspective, CD140a antibodies can be classified into monoclonal and polyclonal antibodies. Monoclonal antibodies are produced by a single B-cell clone, offering high uniformity and specificity, whereas polyclonal antibodies originate from different B-cell clones and can recognize multiple epitopes of an antigen. In research practice, selecting the appropriate antibody type based on experimental needs is crucial. For instance, flow cytometry typically requires highly specific monoclonal antibodies, while western blotting may utilize polyclonal antibodies to enhance detection sensitivity. Quality assessment of CD140a antibodies includes parameters such as specificity, affinity, and titer, which directly impact the reliability of experimental results.

II. How is CD140a Antibody Used for Cell Identification and Sorting?

In stem cell research, CD140a antibody has become an essential tool for identifying and isolating mesenchymal stem cells (MSCs). Through immunomagnetic sorting or flow cytometry, researchers can precisely isolate target cells from heterogeneous cell populations using CD140a antibodies. Experimental data show that CD140a-positive cell populations exhibit typical MSC characteristics, including multipotent differentiation potential and self-renewal capacity. During cell sorting, parameters such as antibody concentration, incubation time, and temperature must be precisely optimized to ensure sorting purity and cell viability.

Research in tissue engineering demonstrates that CD140a antibody-labeled cells exhibit superior differentiation capabilities in osteogenic, chondrogenic, and adipogenic differentiation experiments. For example, under standard induction culture conditions, the osteogenic differentiation efficiency of CD140a-positive cells can exceed 85%, significantly higher than that of unsorted cell populations. This high-efficiency sorting capability makes CD140a antibodies valuable in tissue regeneration medicine research. Furthermore, by combining with other surface marker antibodies such as CD90 and CD105, cell subpopulations can be further refined to obtain purer target cell populations.

III. How is CD140a Antibody Applied in Signal Pathway Research?

The CD140a molecule plays a key role in the PDGF signaling pathway, and CD140a antibody is an important tool for studying this pathway. When PDGF ligands bind to CD140a, the receptor dimerizes and undergoes autophosphorylation, activating downstream signaling cascades. Researchers use CD140a antibodies to capture CD140a proteins and their interacting molecules through co-immunoprecipitation, thereby analyzing the composition of signaling complexes. Western blot analysis shows that CD140a antibodies can specifically detect CD140a protein bands with a molecular weight of approximately 170 kDa, with no cross-reactivity.

In signal transduction mechanism research, the application of CD140a antibodies enables scientists to precisely track the activation process of the PDGF signaling pathway. Experimental results indicate that the phosphorylation level of CD140a receptors peaks within 5 minutes after ligand stimulation and then gradually declines. By using CD140a antibodies that specifically recognize phosphorylation sites, researchers can quantitatively analyze receptor activation kinetics. These studies not only deepen the understanding of cell proliferation and differentiation mechanisms but also provide important clues for related pathological process research.

IV. What Role Does CD140a Antibody Play in Disease Model Construction?

In disease research, CD140a antibodies are widely used in tumor model construction. Preclinical research data show that CD140a is highly expressed in various tumor stromal cells, particularly cancer-associated fibroblasts (CAFs). By using CD140a antibodies to label and isolate these cells, researchers can establish more accurate tumor microenvironment models. In animal models, the application of CD140a antibodies allows scientists to trace the origin and evolution of tumor stromal cells, providing new perspectives for understanding tumor biology.

Research on tissue fibrosis diseases also benefits from the application of CD140a antibodies. Experimental evidence shows that CD140a-positive cells significantly increase in fibrotic lesions, and their quantity is positively correlated with disease severity. In pulmonary fibrosis models, the use of CD140a antibodies enables researchers to quantitatively analyze the activation level of myofibroblasts. These studies not only reveal the critical role of CD140a in fibrosis but also provide experimental basis for developing new therapeutic strategies.

V. What Are the Future Directions for CD140a Antibody Development?

With advancements in proteomics technology, the application prospects of CD140a antibodies continue to expand. Novel antibody engineering technologies, such as nanobodies and bispecific antibodies, offer new possibilities for improving the sensitivity and specificity of CD140a detection. Protein microarray data show that engineered CD140a antibodies maintain high affinity while significantly reducing nonspecific binding. These technological advancements will promote the application of CD140a antibodies in more refined cell sorting and signal transduction research.

In clinical translation, the diagnostic potential of CD140a antibodies is gaining increasing attention. Although current research primarily focuses on basic science, some studies have explored their application value in disease diagnosis. With more validation studies and standardized protocols, CD140a antibodies are expected to become important tools for biomarker detection. Meanwhile, the integration of multi-omics technologies will deepen the understanding of CD140a's biological functions, driving related research to higher levels.

VI. Which Manufacturers Provide CD140a Antibodies?

Hangzhou Start Biotech Co., Ltd. has independently developed "Rat Anti-Mouse CD140a Antibody" (Product Name: Rat Anti-Mouse CD140a Antibody (S-R682), Catalog Number: S0B5178), a high-specificity, high-affinity, and highly stable detection tool for platelet-derived growth factor receptors. This product can accurately identify mouse CD140a (PDGFRα) protein and has significant application value in mouse models of stromal cell development, tissue fibrosis, and tumor microenvironment research.

Professional Technical Support: We provide comprehensive product technical documentation, including complete specificity validation data, experimental protocols, and professional technical support, fully assisting customers in making progress in developmental biology and fibrosis disease research.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-quality, high-value biological reagents and solutions for global innovative pharmaceutical companies and research institutions. For more details about "Rat Anti-Mouse CD140a Antibody" (Catalog Number S0B5178) or to request sample testing, please contact us.

Product Information